Anzeige
Meldung des Tages: 15 Mrd. USD für Polymarket – 16,5 Mio. USD für diesen Newcomer: Entsteht hier die nächste Blue-Chip-Story?

Halozyme Therapeutics News

Aktie
WKN:  A0DLHS ISIN:  US40637H1095 US-Symbol:  HALO Branche:  Biotechnologie Land:  USA
62,12 $
+0,48 $
+0,78%
54,126 € 30.03.26
Depot/Watchlist
Marktkapitalisierung *
7,44 Mrd. €
Streubesitz
-
KGV
10,83
Nachhaltigkeits-Score
40 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,79: JU4FDT
Werbung

Halozyme Therapeutics News

04.11.25 wallstreetONLINE Redaktion
Hebel-Idee | Long-Chance: Warum ausgerechnet auf Novo Nordisk setzen, wenn diese Aktie so viel besser ist?
Während viele Anlegerinnen und Anleger verzweifelt auf einen Turnarnound der Aktie von Novo Nordisk warten, hat Halozyme schon jetzt deutlich mehr zu bieten. Willkommen zum ...
03.11.25 - PR Newswire
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS PR Newswire
21.10.25 - PR Newswire
Halozyme to Report Third Quarter 2025 Financial and Operating Results
Halozyme to Report Third Quarter 2025 Financial and Operating Results PR Newswire
01.10.25 - PR Newswire
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s PR Newswire
28.08.25 - PR Newswire
Halozyme to Participate at Upcoming Investor Conferences
Halozyme to Participate at Upcoming Investor Conferences PR Newswire
06.08.25 - ARIVA.DE Redaktion
Dieses Biotech-Unternehmen schlägt Bayer, Evotec, Novo Nordisk & Co. um Längen!
Während Anlegerinnen und Anleger verzweifelt auf einen Turnaround der Aktien von Bayer, Evotec und Novo Nordisk warten, liefert dieser Rivale konstant Gewinne.
05.08.25 - PR Newswire
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS PR Newswire
23.07.25 - PR Newswire
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma PR Newswire
22.07.25 - PR Newswire
Halozyme to Report Second Quarter 2025 Financial and Operating Results
Halozyme to Report Second Quarter 2025 Financial and Operating Results PR Newswire
30.06.25 - PR Newswire
Halozyme Therapeutics Added to Russell 1000® Index
Halozyme Therapeutics Added to Russell 1000® Index PR Newswire
20.06.25 - PR Newswire
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating ...
28.05.25 - PR Newswire
Halozyme to Participate at Upcoming Investor Conferences
Halozyme to Participate at Upcoming Investor Conferences PR Newswire
28.05.25 - PR Newswire
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-​Formulated with ENHANZE® Across Multiple ...
10.05.25 wallstreetONLINE Redaktion
Community-Rückblick: "Kann dieses verdammte Unternehmen nicht ein Mal positiv überraschen?!"
Das Hamburger Biotech-​Unternehmen Evotec hat am 06. Mai seine Zahlen zum ersten Quartal 2025 präsentiert. Die wo-​Community reagiert überwiegend enttäuscht und steht ...
06.05.25 - PR Newswire
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS PR Newswire
06.05.25 wallstreetONLINE Redaktion
Enttäuschender Jahresauftakt: Evotec: Bitte nicht schon wieder!
Das Hamburger Biotech-​Unternehmen Evotec hat seine Zahlen zum ersten Quartal präsentiert. Die gefallen Anlegerinnen und Anlegern nicht, die Aktie fällt.Trotz der von Bristol-...
05.05.25 - PR Newswire
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference PR Newswire
28.04.25 - PR Newswire
Halozyme to Report First Quarter 2025 Financial and Operating Results
Halozyme to Report First Quarter 2025 Financial and Operating Results PR Newswire
28.04.25 - PR Newswire
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating ...
24.04.25 - PR Newswire
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation PR Newswire

Newssuche

Videos

newspaper
30.03.26 -17,90%
Technical Trading 73% Trefferquote
GBP/USD Long Typ: Turbo Open End WKN: VG541T Hebel:30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »